F

our years ago, ImmunoGen (IMGN) marked a significant achievement in the Waltham, Mass., company’s history with the market debut of Kadcyla, a breast cancer drug that uses innovative biotechnology to target cancer while sparing healthy cells.

The Genentech division of Swiss drug giant Roche won approval from U.S. and European regulators to sell Kadcyla, but the “payload platform” that enables the drug to bind to tumors was painstakingly developed over three decades by ImmunoGen.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.